EDAP TMS S.A. (EDAP) is a stock worth watching after climbing to its 52-week high on the back of record preliminary fourth-quarter and full-year 2025 results. Driven by strong demand for its Focal One High Intensity Focused Ultrasound (HIFU) system, the company posted its highest-ever HIFU revenue and continues to expand adoption across hospitals and urology centers. Backed by FDA clearance for advanced imaging upgrades and solid 2026 revenue guidance, EDAP is strengthening its role as a key innovator in minimally invasive prostate cancer therapy.
Company Overview
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com